In exploring whether valsartan plays a role in the treatment of NPC, Wang et al. 61 revealed that the expression of AT1R was very high in NPC cells, and AT1R blocker valsartan could suppress the secretion of VEGF in NPC cells, thus inhibiting cancer cell growth. This evidence concerns the gene AGTR1 and nasopharyngeal carcinoma.